中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 7
Jul.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(7): 1461-1468

Risk factors for diabetes after liver transplantation and related preventive measures

DOI: 10.12449/JCH250736
  • 1.

    Department of Hepatobiliary Surgery and Liver Transplant Center，The First Hospital of Shanxi Medical University，Taiyuan 030001，China

  • 2.

    The First Clinical Medical College of Shanxi Medical University，Taiyuan 030001，China

  • 3.

    Department of Head and Neck Surgery，Shanxi Provincial Cancer Hospital，Shanxi Hospital Affiliated to Cancer Hospital of Chinese Academy of Medical Sciences，Cancer Hospital Affiliated to Shanxi Medical University，Taiyuan 031000，China

Research funding:

Shanxi Provincial Key Laboratory Project (202204010931008);

Shanxi Central Guidance Local Science and Technology Development Fund Project (YDZJSX2021B012);

National Natural Science Foundation of China (82470693);

Shanxi Key Research and Development Program (202302130501013)

More Information
  • Corresponding author: XU Jun， junxuty@163.com （ORCID： 0000-0003-3755-9660）
  • Received Date: 2024-11-19
  • Accepted Date: 2024-12-02
  • Published Date: 2025-07-25
    Abstract
  • In recent years， as the survival time of liver transplant recipients continues to increase， serious complications after transplantation， including diabetes， which affects the long-term survival of patients， have attracted more and more attention. Diabetes after liver transplantation can increase the risk of infection and cardiovascular disease， which in turn affects the survival rate of grafts and patients， and therefore， identification and intervention for high-risk populations are of great importance for improving the prognosis of patients. This article reviews the risk factors for diabetes after liver transplantation， in order to deepen the understanding of diabetes after liver transplantation and provide a theoretical basis for disease prevention and treatment.

     

    • FullText(HTML)
  • loading
    • References(79)
  • [1]
    STARZL TE. The long reach of liver transplantation[J]. Nat Med, 2012, 18( 10): 1489- 1492. DOI: 10.1038/nm.2927.
    [2]
    YONG JN, LIM WH, NG CH, et al. Outcomes of nonalcoholic steatohepatitis after liver transplantation: An updated meta-analysis and systematic review[J]. Clin Gastroenterol Hepatol, 2023, 21( 1): 45- 54. e 6. DOI: 10.1016/j.cgh.2021.11.014.
    [3]
    ABDALLAH MA, WALEED M, BELL MG, et al. Systematic review with meta-analysis: Liver transplant provides survival benefit in patients with acute on chronic liver failure[J]. Aliment Pharmacol Ther, 2020, 52( 2): 222- 232. DOI: 10.1111/apt.15793.
    [4]
    CHEN YN, XIAO Y, HAN XY, et al. Diagnosis and individualized drug therapy for the rejection with hy-perglycemia after liver Transplantation[J]. Chin J Clin Pharmacol Ther, 2023, 28( 5): 550- 555. DOI: 10.12092/j.issn.1009-2501.2023.05.009.

    陈以宁, 肖云, 韩晓雨, 等. 肝移植术后排斥合并高血糖的诊治和用药的实践与思考[J]. 中国临床药理学与治疗学, 2023, 28( 5): 550- 555. DOI: 10.12092/j.issn.1009-2501.2023.05.009.
    [5]
    LV CY, ZHANG Y, CHEN XY, et al. New-onset diabetes after liver transplantation and its impact on complications and patient survival[J]. J Diabetes, 2015, 7( 6): 881- 890. DOI: 10.1111/1753-0407.12275.
    [6]
    LING Q, XU X, XIE HY, et al. New-onset diabetes after liver transplantation: A national report from China Liver Transplant Registry[J]. Liver Int, 2016, 36( 5): 705- 712. DOI: 10.1111/liv.13042.
    [7]
    RICHARDSON B, KHAN MQ, BROWN SA, et al. Personalizing diabetes management in liver transplant recipients: The new era for optimizing risk management[J]. Hepatol Commun, 2022, 6( 6): 1250- 1261. DOI: 10.1002/hep4.1876.
    [8]
    KOSHY AN, GOW PJ, HAN HC, et al. Sudden cardiac death following liver transplantation: Incidence, trends and risk predictors[J]. Int J Cardiol, 2021, 327: 171- 174. DOI: 10.1016/j.ijcard.2020.11.038.
    [9]
    PAREKH J, CORLEY DA, FENG S. Diabetes, hypertension and hyperlipidemia: Prevalence over time and impact on long-term survival after liver transplantation[J]. Am J Transplant, 2012, 12( 8): 2181- 2187. DOI: 10.1111/j.1600-6143.2012.04077.x.
    [10]
    SHARIF A, HECKING M, de VRIES AJ, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: Recommendations and future directions[J]. Am J Transplant, 2014, 14( 9): 1992- 2000. DOI: 10.1111/ajt.12850.
    [11]
    DONG JF, XUE Q, TENG F, et al. Research progress in risk factors of post-transplantation diabetes mellitus[J]. Organ Transplant, 2024, 15( 1): 145- 150. DOI: 10.3969/j.issn.1674-7445.2023154.

    董骏峰, 薛强, 滕飞, 等. 移植后糖尿病危险因素研究进展[J]. 器官移植, 2024, 15( 1): 145- 150. DOI: 10.3969/j.issn.1674-7445.2023154.
    [12]
    CHIN YH, TAN HQM, NG CH, et al. A time-based meta-analysis on the incidence of new onset diabetes after liver transplantation[J]. J Clin Med, 2021, 10( 5): 1045. DOI: 10.3390/jcm10051045.
    [13]
    LAWENDY B, SRINATHAN S, KOTHA S, et al. Systematic review and meta-analysis of post-transplant diabetes mellitus in liver transplant recipients[J]. Clin Transplant, 2021, 35( 7): e14340. DOI: 10.1111/ctr.14340.
    [14]
    ARAVINTHAN AD, FATEEN W, DOYLE AC, et al. The impact of preexisting and post-transplant diabetes mellitus on outcomes following liver transplantation[J]. Transplantation, 2019, 103( 12): 2523- 2530. DOI: 10.1097/TP.0000000000002757.
    [15]
    LI Z, SUN F, HU Z, et al. New-onset diabetes mellitus in liver transplant recipients with hepatitis C: Analysis of the national database[J]. Transplant Proc, 2016, 48( 1): 138- 144. DOI: 10.1016/j.transproceed.2015.11.010.
    [16]
    van HOOFF JP, CHRISTIAANS MHL, van DUIJNHOVEN EM. Evaluating mechanisms of post-transplant diabetes mellitus[J]. Nephrol Dial Transplant, 2004, 19( Suppl 6): vi8-vi 12. DOI: 10.1093/ndt/gfh1063.
    [17]
    PORRINI EL, DÍAZ JM, MORESO F, et al. Clinical evolution of post-transplant diabetes mellitus[J]. Nephrol Dial Transplant, 2016, 31( 3): 495- 505. DOI: 10.1093/ndt/gfv368.
    [18]
    JENSSEN T, HARTMANN A. Post-transplant diabetes mellitus in patients with solid organ transplants[J]. Nat Rev Endocrinol, 2019, 15( 3): 172- 188. DOI: 10.1038/s41574-018-0137-7.
    [19]
    KOTHA S, LAWENDY B, ASIM S, et al. Impact of immunosuppression on incidence of post-transplant diabetes mellitus in solid organ transplant recipients: Systematic review and meta-analysis[J]. World J Transplant, 2021, 11( 10): 432- 442. DOI: 10.5500/wjt.v11.i10.432.
    [20]
    BHAT V, TAZARI M, WATT KD, et al. New-onset diabetes and preexisting diabetes are associated with comparable reduction in long-term survival after liver transplant: A machine learning approach[J]. Mayo Clin Proc, 2018, 93( 12): 1794- 1802. DOI: 10.1016/j.mayocp.2018.06.020.
    [21]
    LI DW, LU TF, HUA XW, et al. Risk factors for new onset diabetes mellitus after liver transplantation: A meta-analysis[J]. World J Gastroenterol, 2015, 21( 20): 6329- 6340. DOI: 10.3748/wjg.v21.i20.6329.
    [22]
    SHAKED A, DESMARAIS MR, KOPETSKIE H, et al. Outcomes of immunosuppression minimization and withdrawal early after liver transplantation[J]. Am J Transplant, 2019, 19( 5): 1397- 1409. DOI: 10.1111/ajt.15205.
    [23]
    FENG S, BUCUVALAS JC, MAZARIEGOS GV, et al. Efficacy and safety of immunosuppression withdrawal in pediatric liver transplant recipients: Moving toward personalized management[J]. Hepatology, 2021, 73( 5): 1985- 2004. DOI: 10.1002/hep.31520.
    [24]
    SHAKED O, LOZA BL, OLTHOFF KM, et al. Donor and recipient genetics: Implications for the development of posttransplant diabetes mellitus[J]. Am J Transplant, 2024, 24( 10): 1794- 1802. DOI: 10.1016/j.ajt.2024.05.014.
    [25]
    LEE S, LEE M, KIM YE, et al. Association of muscle mass loss with diabetes development in liver transplantation recipients[J]. Diabetes Metab J, 2024, 48( 1): 146- 156. DOI: 10.4093/dmj.2022.0100.
    [26]
    WANG M, XU J, YANG N, et al. Insight into the metabolomic characteristics of post-transplant diabetes mellitus by the integrated LC-MS and GC-MS approach- preliminary study[J]. Front Endocrinol(Lausanne), 2022, 12: 807318. DOI: 10.3389/fendo.2021.807318.
    [27]
    CHEN X, HU K, SHI HZ, et al. Syk/BLNK/NF-κB signaling promotes pancreatic injury induced by tacrolimus and potential protective effect from rapamycin[J]. Biomed Pharmacother, 2024, 171: 116125. DOI: 10.1016/j.biopha.2024.116125.
    [28]
    TRIÑANES J, DIJKE P TEN, GROEN N, et al. Tacrolimus-induced BMP/SMAD signaling associates with metabolic stress-activated FOXO1 to trigger β-cell failure[J]. Diabetes, 2020, 69( 2): 193- 204. DOI: 10.2337/db19-0828.
    [29]
    LI PX, ZHANG R, ZHOU JP, et al. Vancomycin relieves tacrolimus-induced hyperglycemia by eliminating gut bacterial beta-glucuronidase enzyme activity[J]. Gut Microbes, 2024, 16( 1): 2310277. DOI: 10.1080/19490976.2024.2310277.
    [30]
    BAI RP, AN R, CHEN SY, et al. Risk factors and prediction score for new-onset diabetes mellitus after liver transplantation[J]. J Diabetes Investig, 2024, 15( 8): 1105- 1114. DOI: 10.1111/jdi.14204.
    [31]
    SHANG Y, SHAO F, KONG XJ. An analysis of risk factors for the development of diabetes mellitus after orthotopic liver transplanta-tion in adults[J]. J Precis Med, 2024, 39( 4): 341- 345, 351. DOI: 10.13362/j.jpmed.202404013.

    尚莹, 邵非, 孔心涓. 成人原位肝移植术后糖尿病发生的危险因素分析[J]. 精准医学杂志, 2024, 39( 4): 341- 345, 351. DOI: 10.13362/j.jpmed.202404013.
    [32]
    FERNÁNDEZ-RAMÍREZ A, OLIVAS-MARTINEZ A, RUIZ-MANRIQUEZ J, et al. Posttransplantation diabetes mellitus after liver transplant and the impact of family history of diabetes in a Mexican cohort[J]. Rev Gastroenterol Mex(Engl Ed), 2024, 89( 2): 249- 257. DOI: 10.1016/j.rgmxen.2023.06.002.
    [33]
    LI C, ZHANG H, LI CX, et al. Analysis of factors associated with the development of post-transplantation diabetes mellitus and its impact on prognosis[J/CD]. Pract J Organ Transplant Electron Version, 2022, 10( 5): 401- 407. DOI: 10.3969/j.issn.2095-5332.2022.05.005.

    李畅, 张慧, 李长贤, 等. 肝移植后糖尿病发病相关因素分析及预后影响[J/CD]. 实用器官移植电子杂志, 2022, 10( 5): 401- 407. DOI: 10.3969/j.issn.2095-5332.2022.05.005.
    [34]
    CAMPOS MB, RIGUETTO CM, de FÁTIMA SANTANA FERREIRA BOIN I, et al. Risk factors associated with diabetes after liver transplant[J]. Arch Endocrinol Metab, 2022, 66( 2): 182- 190. DOI: 10.20945/2359-3997000000447.
    [35]
    DASCAL R, WIEBE C, NIAZI M, et al. Post-transplant diabetes mellitus in Canadian liver and renal transplant recipients[J]. Can Liver J, 2022, 5( 4): 466- 475. DOI: 10.3138/canlivj-2022-0010.
    [36]
    JEDDI M, AGHASADEGHI F, RANJBAR OMRANI G, et al. Incidence, risk factors, and follow-up of diabetes mellitus after liver transplant: A prospective study from Iran[J]. Exp Clin Transplant, 2021, 19( 9): 928- 934. DOI: 10.6002/ect.2019.0158.
    [37]
    GULSOY KIRNAP N, KIRNAP M, ALSHALABI O, et al. Posttransplant diabetes mellitus incidence and risk factors in adult liver transplantation recipients[J]. Acta Endocrinol(Buchar), 2020, 16( 4): 449- 453. DOI: 10.4183/aeb.2020.449.
    [38]
    LIANG J, YI XL, XUE MJ, et al. A retrospective cohort study of preoperative lipid indices and their impact on new-onset diabetes after liver transplantation[J]. J Clin Lab Anal, 2020, 34( 5): e23192. DOI: 10.1002/jcla.23192.
    [39]
    LING Q, XIE HY, LU D, et al. Association between donor and recipient TCF7L2 gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation in a Han Chinese population[J]. J Hepatol, 2013, 58( 2): 271- 277. DOI: 10.1016/j.jhep.2012.09.025.
    [40]
    SHAKED A, LOZA BL, van LOON E, et al. Donor and recipient polygenic risk scores influence the risk of post-transplant diabetes[J]. Nat Med, 2022, 28( 5): 999- 1005. DOI: 10.1038/s41591-022-01758-7.
    [41]
    CRON DC, NOON KA, COTE DR, et al. Using analytic morphomics to describe body composition associated with post-kidney transplantation diabetes mellitus[J]. Clin Transplant, 2017, 31( 9). DOI: 10.1111/ctr.13040.
    [42]
    PAIS R, SIDNEY BARRITT A 4th, CALMUS Y, et al. NAFLD and liver transplantation: Current burden and expected challenges[J]. J Hepatol, 2016, 65( 6): 1245- 1257. DOI: 10.1016/j.jhep.2016.07.033.
    [43]
    BECKMANN S, NIKOLIC N, DENHAERYNCK K, et al. Evolution of body weight parameters up to 3 years after solid organ transplantation: The prospective Swiss Transplant Cohort Study[J]. Clin Transplant, 2017, 31( 3). DOI: 10.1111/ctr.12896.
    [44]
    FUSSNER LA, HEIMBACH JK, FAN C, et al. Cardiovascular disease after liver transplantation: When, what, and who is at risk[J]. Liver Transpl, 2015, 21( 7): 889- 896. DOI: 10.1002/lt.24137.
    [45]
    BURRA P, BECCHETTI C, GERMANI G. NAFLD and liver transplantation: Disease burden, current management and future challenges[J]. JHEP Rep, 2020, 2( 6): 100192. DOI: 10.1016/j.jhepr.2020.100192.
    [46]
    STEPANOVA M, HENRY L, GARG R, et al. Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis[J]. BMC Gastroenterol, 2015, 15: 175. DOI: 10.1186/s12876-015-0407-y.
    [47]
    RODRÍGUEZ-MORÁN M, GUERRERO-ROMERO F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: A randomized double-blind controlled trial[J]. Diabetes Care, 2003, 26( 4): 1147- 1152. DOI: 10.2337/diacare.26.4.1147.
    [48]
    CHEN SJ, BOWEN DG, LIU K, et al. Hypomagnesaemia, an independent risk factor for the development of post-transplant diabetes mellitus in liver and renal transplant recipients? A systematic review[J]. J Hum Nutr Diet, 2024, 37( 6): 1407- 1419. DOI: 10.1111/jhn.13354.
    [49]
    van LAECKE S, van BIESEN W, VERBEKE F, et al. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation[J]. Am J Transplant, 2009, 9( 9): 2140- 2149. DOI: 10.1111/j.1600-6143.2009.02752.x.
    [50]
    van LAECKE S, CALUWE R, HUYBRECHTS I, et al. Effect of magnesium supplements on insulin secretion after kidney transplantation: A randomized controlled trial[J]. Ann Transplant, 2017, 22: 524- 531. DOI: 10.12659/aot.903439.
    [51]
    van LAECKE S, DESIDERI F, GEERTS A, et al. Hypomagnesemia and the risk of new-onset diabetes after liver transplantation[J]. Liver Transpl, 2010, 16( 11): 1278- 1287. DOI: 10.1002/lt.22146.
    [52]
    SEPEHRI Z, KIANI Z, AFSHARI M, et al. Inflammasomes and type 2 diabetes: An updated systematic review[J]. Immunol Lett, 2017, 192: 97- 103. DOI: 10.1016/j.imlet.2017.10.010.
    [53]
    HELDAL TF, UELAND T, JENSSEN T, et al. Inflammatory and related biomarkers are associated with post-transplant diabetes mellitus in kidney recipients: A retrospective study[J]. Transpl Int, 2018, 31( 5): 510- 519. DOI: 10.1111/tri.13116.
    [54]
    XUE MJ, LV CY, CHEN XY, et al. Effect of interleukin-2 receptor antagonists on new-onset diabetes after liver transplantation: A retrospective cohort study[J]. J Diabetes, 2016, 8( 4): 579- 587. DOI: 10.1111/1753-0407.12356.
    [55]
    SCARONI C, ZILIO M, FOTI M, et al. Glucose metabolism abnormalities in cushing syndrome: From molecular basis to clinical management[J]. Endocr Rev, 2017, 38( 3): 189- 219. DOI: 10.1210/er.2016-1105.
    [56]
    DAVIDSON J, WILKINSON A, DANTAL J, et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003[J]. Transplantation, 2003, 75( 10 Suppl): SS3- S24. DOI: 10.1097/01.TP.0000069952.49242.3E.
    [57]
    SONG JL, GAO W, ZHONG Y, et al. Minimizing tacrolimus decreases the risk of new-onset diabetes mellitus after liver transplantation[J]. World J Gastroenterol, 2016, 22( 6): 2133- 2141. DOI: 10.3748/wjg.v22.i6.2133.
    [58]
    TRIÑANES J, RODRIGUEZ-RODRIGUEZ AE, BRITO-CASILLAS Y, et al. Deciphering tacrolimus-induced toxicity in pancreatic β cells[J]. Am J Transplant, 2017, 17( 11): 2829- 2840. DOI: 10.1111/ajt.14323.
    [59]
    RADU RG, FUJIMOTO S, MUKAI ER, et al. Tacrolimus suppresses glucose-induced insulin release from pancreatic islets by reducing glucokinase activity[J]. Am J Physiol Endocrinol Metab, 2005, 288( 2): E365- E371. DOI: 10.1152/ajpendo.00390.2004.
    [60]
    JOHNSTON O, ROSE CL, WEBSTER AC, et al. Sirolimus is associated with new-onset diabetes in kidney transplant recipients[J]. J Am Soc Nephrol, 2008, 19( 7): 1411- 1418. DOI: 10.1681/ASN.2007111202.
    [61]
    TEUTONICO A, SCHENA PF, di PAOLO S. Glucose metabolism in renal transplant recipients: Effect of calcineurin inhibitor withdrawal and conversion to sirolimus[J]. J Am Soc Nephrol, 2005, 16( 10): 3128- 3135. DOI: 10.1681/ASN.2005050487.
    [62]
    GRANATA S, MERCURI S, TROISE D, et al. mTOR-inhibitors and post-transplant diabetes mellitus: A link still debated in kidney transplantation[J]. Front Med(Lausanne), 2023, 10: 1168967. DOI: 10.3389/fmed.2023.1168967.
    [63]
    KLEIN K, NELSON J, LONG C, et al. Effect of hepatitis C viremia on posttransplant diabetes mellitus in liver transplant recipients[J]. Prog Transplant, 2022, 32( 1): 73- 77. DOI: 10.1177/15269248211064879.
    [64]
    YOUNOSSI Z, STEPANOVA M, SAAB S, et al. The association of hepatitis C virus infection and post-liver transplant diabetes: Data from 17 000 HCV-infected transplant recipients[J]. Aliment Pharmacol Ther, 2015, 41( 2): 209- 217. DOI: 10.1111/apt.13027.
    [65]
    DELGADO-BORREGO A, LIU YS, JORDAN SH, et al. Prospective study of liver transplant recipients with HCV infection: Evidence for a causal relationship between HCV and insulin resistance[J]. Liver Transpl, 2008, 14( 2): 193- 201. DOI: 10.1002/lt.21267.
    [66]
    KAWAGUCHI Y, MIZUTA T. Interaction between hepatitis C virus and metabolic factors[J]. World J Gastroenterol, 2014, 20( 11): 2888- 2901. DOI: 10.3748/wjg.v20.i11.2888.
    [67]
    MORBITZER KA, TABER DJ, PILCH NA, et al. The impact of diabetes mellitus and glycemic control on clinical outcomes following liver transplant for hepatitis C[J]. Clin Transplant, 2014, 28( 8): 862- 868. DOI: 10.1111/ctr.12391.
    [68]
    LIZAOLA-MAYO BC, RODRIGUEZ EA. Cytomegalovirus infection after liver transplantation[J]. World J Transplant, 2020, 10( 7): 183- 190. DOI: 10.5500/wjt.v10.i7.183.
    [69]
    ZHANG Z, SUN JY, GUO M, et al. Progress of new-onset diabetes after liver and kidney transplantation[J]. Front Endocrinol(Lausanne), 2023, 14: 1091843. DOI: 10.3389/fendo.2023.1091843.
    [70]
    YADAV AD, CHANG YH, AQEL BA, et al. New onset diabetes mellitus in living donor versus deceased donor liver transplant recipients: Analysis of the UNOS/OPTN database[J]. J Transplant, 2013, 2013: 269096. DOI: 10.1155/2013/269096.
    [71]
    XUE MJ, LV CY, CHEN XY, et al. Donor liver steatosis: A risk factor for early new-onset diabetes after liver transplantation[J]. J Diabetes Investig, 2017, 8( 2): 181- 187. DOI: 10.1111/jdi.12560.
    [72]
    CRUZ-JENTOFT AJ, SAYER AA. Sarcopenia[J]. Lancet, 2019, 393( 10191): 2636- 2646. DOI: 10.1016/s0140-6736(19)31138-9.
    [73]
    TSIEN C, GARBER A, NARAYANAN A, et al. Post-liver transplantation sarcopenia in cirrhosis: A prospective evaluation[J]. J Gastroenterol Hepatol, 2014, 29( 6): 1250- 1257. DOI: 10.1111/jgh.12524.
    [74]
    KUO SZ, AHMAD M, DUNN MA, et al. Sarcopenia predicts post-transplant mortality in acutely ill men undergoing urgent evaluation and liver transplantation[J]. Transplantation, 2019, 103( 11): 2312- 2317. DOI: 10.1097/TP.0000000000002741.
    [75]
    PARK SJ, YOON JH, JOO I, et al. Newly developed sarcopenia after liver transplantation, determined by a fully automated 3D muscle volume estimation on abdominal CT, can predict post-transplant diabetes mellitus and poor survival outcomes[J]. Cancer Imaging, 2023, 23( 1): 73. DOI: 10.1186/s40644-023-00593-4.
    [76]
    LEE DU, HAN J, LEE KJ, et al. The clinical implications of pre-liver transplant diabetes on post-liver transplant outcomes in patients with NASH: Analysis of the UNOS database[J]. Hepatol Int, 2022, 16( 6): 1448- 1457. DOI: 10.1007/s12072-022-10414-8.
    [77]
    ROCCARO GA, MITRANI R, HWANG WT, et al. Sustained virological response is associated with a decreased risk of posttransplant diabetes mellitus in liver transplant recipients with hepatitis C-related liver disease[J]. Liver Transpl, 2018, 24( 12): 1665- 1672. DOI: 10.1002/lt.25351.
    [78]
    ZHANG L, HU P. Hepatitis C virus infection and organ transplantation[J]. J Clin Hepatol, 2024, 40( 4): 665- 671. DOI: 10.12449/JCH240404.

    张莉, 胡鹏. 丙型肝炎病毒感染与器官移植[J]. 临床肝胆病杂志, 2024, 40( 4): 665- 671. DOI: 10.12449/JCH240404.
    [79]
    XIAO ZN, LI JH, JIANG J, et al. Recent progress on diabetes mellitus after liver transplantation[J]. Organ Transplant, 2021, 12( 5): 630- 636. DOI: 10.3969/j.issn.1674-7445.2021.05.020.

    肖正楠, 李俊辉, 蒋捷, 等. 肝移植术后糖尿病的最新进展[J]. 器官移植, 2021, 12( 5): 630- 636. DOI: 10.3969/j.issn.1674-7445.2021.05.020.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (387) PDF downloads(23) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return